Skip to main content
Top
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 9/2020

01-09-2020 | Neurophthalmology

Diagnosis and management of three optic neuropathies: a national survey

Authors: Haeng-Jin Lee, Hyuna Kim, Ju-Yeun Lee

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 9/2020

Login to get access

Abstract

Background

We aimed to evaluate the current practice patterns of neuro-ophthalmologists in diagnosis and management of three optic neuropathies using a national survey in South Korea and to further compare the practices of neuro-ophthalmologists divided into junior and senior groups based on their clinical practice experience.

Methods

An anonymous, 15-question survey on the diagnosis and treatment of traumatic optic neuropathy (TON), nonarteritic anterior ischemic optic neuropathy (NAION), and Leber’s hereditary optic neuropathy (LHON) was sent to all neuro-ophthalmologists registered with the Korean Neuro-ophthalmology Society. The questions addressed physician’s practice duration as neuro-ophthalmologist, choices of MRI scans and laboratory tests for the diagnosis in suspected optic neuropathy, clinical experiences with steroids (e.g., side effects), and choices of treatment modalities and reason in in each optic neuropathy. All participants were classified into senior (≥ 10 years) and junior (< 10 years) groups.

Results

A total of 63 responders (response rate 78.8%) answered the questionnaire. All responders performed the basic blood tests and brain imaging for evaluating optic neuropathy. Observation was the most preferred option for TON (47.6%) and NAION (63.5%). Steroid use was the second most preferred, and the most selected indication of steroid was “when the patient wants” (58.7%) for TON and “severe visual loss or last eye” (66%) for NAION. The most preferred treatment for LHON was “prescribing idebenone” (69.7%) with a dose of 900 mg/day (63.8%). Forty-nine respondents (77.8%) experienced side effects of steroids. There was no significant difference between the senior and junior groups in all questionnaire answers (all p > 0.05).

Conclusion

Optic neuropathies are being managed similarly by the two groups in South Korea, and many of them still use steroids. We provided reliable reasons for our results compared with other countries.
Appendix
Available only for authorised users
Literature
1.
go back to reference Newman NJ, Lott MT, Wallace DC (1991) The clinical characteristics of pedigrees of Leber's hereditary optic neuropathy with the 11778 mutation. Am J Ophthalmol 111:750–762CrossRef Newman NJ, Lott MT, Wallace DC (1991) The clinical characteristics of pedigrees of Leber's hereditary optic neuropathy with the 11778 mutation. Am J Ophthalmol 111:750–762CrossRef
2.
go back to reference Nikoskelainen EK, Huoponen K, Juvonen V, Lamminen T, Nummelin K, Savontaus ML (1996) Ophthalmologic findings in Leber hereditary optic neuropathy, with special reference to mtDNA mutations. Ophthalmology 103:504–514CrossRef Nikoskelainen EK, Huoponen K, Juvonen V, Lamminen T, Nummelin K, Savontaus ML (1996) Ophthalmologic findings in Leber hereditary optic neuropathy, with special reference to mtDNA mutations. Ophthalmology 103:504–514CrossRef
3.
go back to reference Newman NJ, Biousse V, Newman SA, Bhatti MT, Hamilton SR, Farris BK, Lesser RL, Turbin RE (2006) Progression of visual field defects in leber hereditary optic neuropathy: experience of the LHON treatment trial. Am J Ophthalmol 141:1061–1067CrossRef Newman NJ, Biousse V, Newman SA, Bhatti MT, Hamilton SR, Farris BK, Lesser RL, Turbin RE (2006) Progression of visual field defects in leber hereditary optic neuropathy: experience of the LHON treatment trial. Am J Ophthalmol 141:1061–1067CrossRef
4.
go back to reference Carelli V, Carbonelli M, de Coo IF, Kawasaki A, Klopstock T, Lagreze WA, La Morgia C, Newman NJ, Orssaud C, Pott JWR, Sadun AA, van Everdingen J, Vignal-Clermont C, Votruba M, Yu-Wai-Man P, Barboni P (2017) International consensus statement on the clinical and therapeutic management of Leber hereditary optic neuropathy. J Neuroophthalmol 37:371–381CrossRef Carelli V, Carbonelli M, de Coo IF, Kawasaki A, Klopstock T, Lagreze WA, La Morgia C, Newman NJ, Orssaud C, Pott JWR, Sadun AA, van Everdingen J, Vignal-Clermont C, Votruba M, Yu-Wai-Man P, Barboni P (2017) International consensus statement on the clinical and therapeutic management of Leber hereditary optic neuropathy. J Neuroophthalmol 37:371–381CrossRef
5.
go back to reference Kaderli B, Avci R, Yucel A, Guler K, Gelisken O (2007) Intravitreal triamcinolone improves recovery of visual acuity in nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol 27:164–168CrossRef Kaderli B, Avci R, Yucel A, Guler K, Gelisken O (2007) Intravitreal triamcinolone improves recovery of visual acuity in nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol 27:164–168CrossRef
6.
go back to reference Hayreh SS, Zimmerman MB (2008) Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy. Graefes Arch Clin Exp Ophthalmol 246:1029–1046CrossRef Hayreh SS, Zimmerman MB (2008) Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy. Graefes Arch Clin Exp Ophthalmol 246:1029–1046CrossRef
7.
go back to reference Yaman A, Selver OB, Saatci AO, Soylev MF (2008) Intravitreal triamcinolone acetonide injection for acute non-arteritic anterior ischaemic optic neuropathy. Clin Exp Optom 91:561–564CrossRef Yaman A, Selver OB, Saatci AO, Soylev MF (2008) Intravitreal triamcinolone acetonide injection for acute non-arteritic anterior ischaemic optic neuropathy. Clin Exp Optom 91:561–564CrossRef
8.
go back to reference Kupersmith MJ, Miller NR, Levin LA (2017) New treatments in neuro-ophthalmology: the role for evidence. J Neuroophthalmol 37:1–2CrossRef Kupersmith MJ, Miller NR, Levin LA (2017) New treatments in neuro-ophthalmology: the role for evidence. J Neuroophthalmol 37:1–2CrossRef
9.
go back to reference Berry S, Lin WV, Sadaka A, Lee AG (2017) Nonarteritic anterior ischemic optic neuropathy: cause, effect, and management. Eye Brain 9:23–28CrossRef Berry S, Lin WV, Sadaka A, Lee AG (2017) Nonarteritic anterior ischemic optic neuropathy: cause, effect, and management. Eye Brain 9:23–28CrossRef
10.
go back to reference Lee AG, Biousse V (2010) Should steroids be offered to patients with nonarteritic anterior ischemic optic neuropathy? J Neuroophthalmol 30:193–198CrossRef Lee AG, Biousse V (2010) Should steroids be offered to patients with nonarteritic anterior ischemic optic neuropathy? J Neuroophthalmol 30:193–198CrossRef
11.
go back to reference Entezari M, Rajavi Z, Sedighi N, Daftarian N, Sanagoo M (2007) High-dose intravenous methylprednisolone in recent traumatic optic neuropathy; a randomized double-masked placebo-controlled clinical trial. Graefes Arch Clin Exp Ophthalmol 245:1267–1271CrossRef Entezari M, Rajavi Z, Sedighi N, Daftarian N, Sanagoo M (2007) High-dose intravenous methylprednisolone in recent traumatic optic neuropathy; a randomized double-masked placebo-controlled clinical trial. Graefes Arch Clin Exp Ophthalmol 245:1267–1271CrossRef
12.
go back to reference Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, Eisenberg HM, Flamm E, Leo-Summers L, Maroon J et al (1990) A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the second national acute spinal cord injury study. N Engl J Med 322:1405–1411CrossRef Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, Eisenberg HM, Flamm E, Leo-Summers L, Maroon J et al (1990) A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the second national acute spinal cord injury study. N Engl J Med 322:1405–1411CrossRef
13.
go back to reference Levin LA, Beck RW, Joseph MP, Seiff S, Kraker R (1999) The treatment of traumatic optic neuropathy: the international optic nerve trauma study. Ophthalmology 106:1268–1277CrossRef Levin LA, Beck RW, Joseph MP, Seiff S, Kraker R (1999) The treatment of traumatic optic neuropathy: the international optic nerve trauma study. Ophthalmology 106:1268–1277CrossRef
14.
go back to reference Seiff SR (1990) High dose corticosteroids for treatment of vision loss due to indirect injury to the optic nerve. Ophthalmic Surg 21:389–395PubMed Seiff SR (1990) High dose corticosteroids for treatment of vision loss due to indirect injury to the optic nerve. Ophthalmic Surg 21:389–395PubMed
15.
go back to reference Spoor TC, McHenry JG (1996) Management of traumatic optic neuropathy. J Craniomaxillofac Trauma 2:14–26 discussion 27PubMed Spoor TC, McHenry JG (1996) Management of traumatic optic neuropathy. J Craniomaxillofac Trauma 2:14–26 discussion 27PubMed
16.
go back to reference Biousse V, Calvetti O, Drews-Botsch CD, Atkins EJ, Sathornsumetee B, Newman NJ (2009) Management of optic neuritis and impact of clinical trials: an international survey. J Neurol Sci 276:69–74CrossRef Biousse V, Calvetti O, Drews-Botsch CD, Atkins EJ, Sathornsumetee B, Newman NJ (2009) Management of optic neuritis and impact of clinical trials: an international survey. J Neurol Sci 276:69–74CrossRef
17.
go back to reference Atkins EJ, Drews-Botsch CD, Newman NJ, Calvetti O, Swanson S, Biousse V (2008) Management of optic neuritis in Canada: survey of ophthalmologists and neurologists. Can J Neurol Sci 35:179–184CrossRef Atkins EJ, Drews-Botsch CD, Newman NJ, Calvetti O, Swanson S, Biousse V (2008) Management of optic neuritis in Canada: survey of ophthalmologists and neurologists. Can J Neurol Sci 35:179–184CrossRef
18.
go back to reference Lueck CJ, Danesh-Meyer HV, Margrie FJ, Drews-Botsch C, Calvetti O, Newman NJ, Biousse V (2008) Management of acute optic neuritis: a survey of neurologists and ophthalmologists in Australia and New Zealand. J Clin Neurosci 15:1340–1345CrossRef Lueck CJ, Danesh-Meyer HV, Margrie FJ, Drews-Botsch C, Calvetti O, Newman NJ, Biousse V (2008) Management of acute optic neuritis: a survey of neurologists and ophthalmologists in Australia and New Zealand. J Clin Neurosci 15:1340–1345CrossRef
19.
go back to reference Steinsapir KD, Seiff SR, Goldberg RA (2002) Traumatic optic neuropathy: where do we stand? Ophthalmic Plast Reconstr Surg 18:232–234CrossRef Steinsapir KD, Seiff SR, Goldberg RA (2002) Traumatic optic neuropathy: where do we stand? Ophthalmic Plast Reconstr Surg 18:232–234CrossRef
20.
go back to reference Steinsapir KD, Goldberg RA, Sinha S, Hovda DA (2000) Methylprednisolone exacerbates axonal loss following optic nerve trauma in rats. Restor Neurol Neurosci 17:157–163PubMed Steinsapir KD, Goldberg RA, Sinha S, Hovda DA (2000) Methylprednisolone exacerbates axonal loss following optic nerve trauma in rats. Restor Neurol Neurosci 17:157–163PubMed
21.
go back to reference Steinsapir KD (2006) Treatment of traumatic optic neuropathy with high-dose corticosteroid. J Neuroophthalmol 26:65–67CrossRef Steinsapir KD (2006) Treatment of traumatic optic neuropathy with high-dose corticosteroid. J Neuroophthalmol 26:65–67CrossRef
22.
go back to reference Kumaran AM, Sundar G, Chye LT (2015) Traumatic optic neuropathy: a review. Craniomaxillofac Trauma Reconstr 8:31–41CrossRef Kumaran AM, Sundar G, Chye LT (2015) Traumatic optic neuropathy: a review. Craniomaxillofac Trauma Reconstr 8:31–41CrossRef
23.
go back to reference Brown SM (2019) Re: Saxena et al.: steroids versus no steroids in nonarteritic anterior ischemic optic neuropathy: a randomized controlled trial (ophthalmology. 2018;125:1623-1627). Ophthalmology 126:e46–e47CrossRef Brown SM (2019) Re: Saxena et al.: steroids versus no steroids in nonarteritic anterior ischemic optic neuropathy: a randomized controlled trial (ophthalmology. 2018;125:1623-1627). Ophthalmology 126:e46–e47CrossRef
24.
go back to reference Modarres M, Falavarjani KG, Nazari H, Sanjari MS, Aghamohammadi F, Homaii M, Samiy N (2011) Intravitreal erythropoietin injection for the treatment of non-arteritic anterior ischaemic optic neuropathy. Br J Ophthalmol 95:992–995CrossRef Modarres M, Falavarjani KG, Nazari H, Sanjari MS, Aghamohammadi F, Homaii M, Samiy N (2011) Intravitreal erythropoietin injection for the treatment of non-arteritic anterior ischaemic optic neuropathy. Br J Ophthalmol 95:992–995CrossRef
25.
go back to reference Jehle T, Meschede W, Dersch R, Feltgen N, Bach M, Lagreze WA (2010) Erythropoietin protects retinal ganglion cells and visual function after ocular ischemia and optic nerve compression. Ophthalmologe 107:347–353CrossRef Jehle T, Meschede W, Dersch R, Feltgen N, Bach M, Lagreze WA (2010) Erythropoietin protects retinal ganglion cells and visual function after ocular ischemia and optic nerve compression. Ophthalmologe 107:347–353CrossRef
Metadata
Title
Diagnosis and management of three optic neuropathies: a national survey
Authors
Haeng-Jin Lee
Hyuna Kim
Ju-Yeun Lee
Publication date
01-09-2020
Publisher
Springer Berlin Heidelberg
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 9/2020
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-020-04711-x

Other articles of this Issue 9/2020

Graefe's Archive for Clinical and Experimental Ophthalmology 9/2020 Go to the issue